TICKERNERD
Menu
AURAAURAHealthcare · Biotechnology

AURA Stock Forecast: Aura Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$7.80
+0.39% on the day

The 6 Wall Street analysts covering Aura Biosciences, Inc. hold a median 12-month price target of $15 — +92.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$808.9M
Ticker Nerd rank
41 / 100
Median analyst target
$15
Analysts covering
6
Total return, dividends reinvested
1W
+1.4%
1M
+11.0%
YTD
+43.1%
1Y
+20.6%
From 52W high
−12.4%
From 52W low
+56.9%
$4.97
$8.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aura Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
64
Value
63
Accruals
62
Momentum
58
Quality
50
Size
48
Growth
44
Issuance
37
Revisions
30

Volatility (64): The share price has been relatively steady.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26AURAHigh $23Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $12Median $15High $23

The green dot is the last close — the median target sits +92.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.MaintainsBuy$24 → $18
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy$22 → $24
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025Evercore ISI GroupReinstatesOutperform$13
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025HC Wainwright & Co.AssumesBuy$22
23 May 2025JMP SecuritiesReiteratesMarket Outperform—
26 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
26 Mar 2025JMP SecuritiesMaintainsMarket Outperform—
25 Mar 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024JMP SecuritiesMaintainsMarket Outperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024BTIGMaintainsBuy—
18 Oct 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2024ScotiabankMaintainsSector Outperform—
13 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Sept 2024JMP SecuritiesMaintainsMarket Outperform—
28 Aug 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Aura Biosciences, Inc. (AURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.4×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−3.7×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−53.5%

Higher than 20% of US stocks

Return on assets
−31.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AURAAura Biosciences, Inc.$808.9M
41
ACHVAchieve Life Sciences, Inc.$820.2M
29
FTHFaeth Therapeutics, Inc.$824.9M
54
GYREGyre Therapeutics, Inc.$770.4M
39
RIGLRigel Pharmaceuticals, Inc.$849.1M
79
TBPHTheravance Biopharma, Inc.$856.6M
89
STTKShattuck Labs, Inc.$755.7M
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aura Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AURA news & analysis

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Seeking Alpha · 12 Aug 2026positive

Aura Biosciences is advancing Bel-sar for early choroidal melanoma, with the Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027. Phase 2 data showed 80% tumor control and a strong safety profile, and the company recently completed a C-suite overhaul and a $299 million capital raise, with funding expected to last into 2029.

Why it matters — AURA watchers would care because the streamlined management and extended cash runway position the company to reach its pivotal Phase 3 readout for Bel-sar, a potential first-in-class treatment in a field with significant unmet need.

FAQ

Frequently asked questions about AURA stock

What is the AURA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Aura Biosciences, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AURA stock a buy right now?

Of the 6 analysts covering Aura Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aura Biosciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AURA?

As at 22 Aug 2026, Aura Biosciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (64 of 100).

Will AURA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +92.3% from the last close, and Ticker Nerd's factor model ranks Aura Biosciences, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AURA stock forecast for 2030?

No analyst covering Aura Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.

How has AURA stock performed over the past year?

Aura Biosciences, Inc. returned +20.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aura Biosciences, Inc. do?

Aura Biosciences Inc. is a clinical-stage biotechnology company developing precision immunotherapies for solid tumors, designed to preserve organ function in cancer patients.

What is the latest news on AURA?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval". Aura Biosciences is advancing Bel-sar for early choroidal melanoma, with the Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027. Phase 2 data showed 80% tumor control and a strong safety profile, and the company recently completed a C-suite overhaul and a $299 million capital raise, with funding expected to last into 2029.

Company

About Aura Biosciences, Inc.

Aura Biosciences Inc. is a clinical-stage biotechnology company developing precision immunotherapies for solid tumors, designed to preserve organ function in cancer patients. The company leverages a proprietary platform using virus-like particles, or VLPs, conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates, or VDCs, enabling targeted treatment of various solid tumors. Its lead candidate, bel-sar (belzupacap sarotalocan), is in late-stage clinical development for primary choroidal melanoma and other ocular oncology indications, and in early-stage development for bladder cancer. This approach aims to selectively destroy cancer cells while activating the immune system for long-lasting anti-tumor effects. Aura Biosciences focuses on oncology, particularly in ocular and urologic cancers, serving oncologists and healthcare institutions primarily in the United States. Founded in 2009 and headquartered in Cambridge, Massachusetts, the company operates in the biotechnology sector, advancing therapies for rare and challenging cancer types where traditional treatments often compromise vision or organ function.

CEO Ms. Natalie C. Holles · 113 employees · United States · https://www.aurabiosciences.com